Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 7/20 | 0.45 |
| ▸ | MAOA | P21397 | 6/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098592 | 0.94 | PPARD (0.48) | PPARDPPARGPPARAMAOBMAOA | |
| SCHEMBL6100791 | 0.92 | PPARD (0.44) | PPARDPPARGPPARAMAOBMAOA | |
| SCHEMBL6097466 | 0.84 | MAOB (0.44) | PPARDPPARGPPARAMAOBMAOA | |
| SCHEMBL6100606 | 0.82 | PPARD (0.46) | PPARDPPARGPPARAMAOBMAOA | |
| SCHEMBL6099511 | 0.81 | MAOB (0.41) | PPARDPPARGPPARAMAOBMAOA | |
| SCHEMBL6799799 | 0.80 | PPARG (0.41) | PPARDPPARGPPARAMAOBMAOA | |
| SCHEMBL6098735 | 0.78 | BAZ2B (0.48) | PPARDPPARGPPARAMAOBMAOA | |
| SCHEMBL6100670 | 0.77 | MAOB (0.43) | MAOBMAOAHTR6 | |
| SCHEMBL6099154 | 0.76 | HTR6 (0.52) | MAOBMAOAHTR6 | |
| SCHEMBL6099113 | 0.74 | HTR6 (0.50) | MAOBMAOAHTR6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | PPARD 526/4885PPARG 575/4885PPARA 621/4885 |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | PPARD 437/4885PPARG 476/4885PPARA 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.